Brind.

Analyst Ratings Compare Oncocyte and Alnylam Pharmaceuticals Investment Profiles

1 report, 1 independent Updated Oct 21
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MarketBeat published an investment comparison contrasting Oncocyte and Alnylam Pharmaceuticals. The report analyzed the two healthcare companies based on metrics including institutional ownership, volatility, profitability, and valuation. The comparison noted that Alnylam Pharmaceuticals has higher gross revenue and earnings than Oncocyte, while Oncocyte trades at a lower price-to-earnings ratio than Alnylam Pharmaceuticals.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The comparison provides investors with contrasting financial profiles for both companies. Oncocyte is noted as having higher volatility, with a beta of 1.8, compared to Alnylam Pharmaceuticals' beta of 0.28. Furthermore, Oncocyte has 55.3% institutional ownership, while Alnylam Pharmaceuticals has 93.0% institutional ownership.

From dailypolitical.com

Who's involved

  • Alnylam PharmaceuticalsBiopharmaceutical company compared in the investment analysis
  • AstraZenecaBritish-Swedish pharmaceutical company mentioned in the context of Alnylam Pharmaceuticals

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped